Proactive Investors - Run By Investors For Investors

Pressure BioSciences shares jump after life sciences company sets up Center of Excellence at NYU lab

Dr. Christine Vogel’s lab, which focuses on the study of proteins, will enjoy free use of Pressure BioSciences’s primary instrument system, the Barocycler 2320EXTREME, until the close of 2020
pair of test tubes
Dr Vogel, an associate professor at NYU, is an expert in the study of proteins

Pressure BioSciences Inc (OTCMKTS:PBIO) on Wednesday announced the establishment of a Center of Excellence at Dr. Christine Vogel’s laboratory at New York University’s Center for Genomics and Systems Biology.

As part of this new distinction, Dr Vogel’s lab will enjoy free use of Pressure BioSciences’s primary instrument system, the Barocycler 2320EXTREME, known as the ‘2320EXT’ until the close of 2020.

Under the new collaboration, Dr. Vogel and her colleagues, as well as visitors to her lab, will use the company’s patented pressure cycling technology platform as an aid in the development and confirmation of protocols for tissue-based protein studies that may go on to be used in clinical trials.

READ: Tests show Pressure BioSciences' Ultra Shear Technology effective for processing CBD oil

Investors applauded the news, sending Pressure BioSciences shares up 6.25% to $3.40 in afternoon trade on Wednesday.

Dr Vogel, an associate professor at NYU, is an expert in the study of proteins and their relationship to cancer and other diseases. Dr Vogel’s lab uses the latest equipment and methods to examine the properties of proteins and their association with diseases.

“The 2320 EXT is currently used by research scientists worldwide for the safe, rapid and reproducible lysis of cells and tissues, to release proteins and other important biomolecules (DNA, RNA and lipids) for analysis,” said Roxana McCloskey, Pressure BioSciences’s global director of sales and marketing, in a statement.

READ: Pressure BioSciences' PCT platform could play key role in improving cancer diagnosis

“Such analyses are a critical step in the discovery and development of diagnostic, prognostic and predictive clinical tests used to identify risk, disease presence or disease progression, and to guide treatment in many diseases such as cancer,” McCloskey added.

Dr Vogel is enthusiastic about the introduction of the ‘2320EXT’ to her lab.

“My laboratory uses the most advanced technologies available to investigate the regulation of proteins in different systems in response to environmental stress,” Vogel said in a statement. “We continually look for powerful, cutting-edge tools to help us reach the highest level of quality possible in our research.”

Richard Schumacher, Pressure Bio’s CEO, is similiarly bullish on the partnership and calls Vogel "a thought leader" in the study of proteins.

"To have a scientist of the caliber of Professor Vogel and an institute like the Center for Genomics and Systems Biology, and a university like NYU agree to be recognized as a Center of Excellence speaks volumes of what they think about PBI and our pressure technology platforms," Schumacher wrote in an email to Proactive Investors.

The NYU Center for Genomics and Systems Biology is considered a “hub of science” in New York City. Its facilities include “loft laboratories” where scientists gather to investigate genomics and systems biology.

Thanks to the new partnership, the Vogel laboratory will be open to scientists for workshops and seminars on the use of ‘2320EXT’ in the identification of proteins that might be involved in disease.

Headquartered in South Easton, Massachusetts, Pressure BioSciences provides high pressure-based scientific instruments for biomarker discovery, drug design and development, food science, forensics and counter-bioterror applications.

Contact Ellen Kelleher at [email protected]

-- This story is updated to reflect latest share price movement --

 

View full PBIO profile View Profile

Pressure BioSciences Inc. Timeline

Related Articles

An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use